4,486 Shares in Moderna, Inc. $MRNA Bought by Park Avenue Securities LLC

Park Avenue Securities LLC purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 4,486 shares of the company’s stock, valued at approximately $864,000.

Several other institutional investors also recently bought and sold shares of the business. Apollon Wealth Management LLC lifted its stake in shares of Moderna by 13.6% during the third quarter. Apollon Wealth Management LLC now owns 5,973 shares of the company’s stock worth $1,150,000 after purchasing an additional 713 shares in the last quarter. Aries Wealth Management purchased a new stake in shares of Moderna in the third quarter worth about $385,000. Kingswood Wealth Advisors LLC acquired a new stake in shares of Moderna in the third quarter valued at about $348,000. Sigma Planning Corp acquired a new stake in shares of Moderna in the third quarter valued at about $287,000. Finally, EULAV Asset Management purchased a new stake in shares of Moderna during the 3rd quarter valued at about $1,873,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on MRNA shares. Evercore boosted their price target on Moderna from $50.00 to $80.00 in a research report on Thursday, October 8th. William Blair downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 27th. UBS Group reaffirmed a “neutral” rating on shares of Moderna in a research report on Tuesday, September 22nd. Bradesco Corretora upgraded shares of Moderna to an “outperform” rating in a research note on Friday, August 28th. Finally, Barclays boosted their target price on shares of Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a research report on Monday, August 24th. Six analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $107.10.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck’s personalized cancer vaccine intismeran, used with Keytruda, reduced the risk of death or melanoma recurrence by 42% in a late-stage trial. The results bolster the candidate’s potential, though success in additional cancers and eventual commercial impact are not assured. Article: Moderna’s Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success
• Neutral Sentiment: Moderna is scheduled to report third-quarter results on Nov. 6. Analysts expect sales of about $888.8 million and a loss of $1.37 per share, making the report a near-term catalyst for investors. Article: Buy Moderna Stock Before Q3 Earnings? Here’s What to Know
• Negative Sentiment: Recent coverage warns that the stock’s steep rally and premium valuation could leave it vulnerable if earnings or vaccine-development news disappoints. One article also flags an obstacle to the cancer vaccine’s success, though the supplied article summary does not specify what it is. Article: Buy Moderna Stock Before Q3 Earnings? Here’s What to Know
• Neutral Sentiment: Prediction markets have begun trading on FDA approval timing for the melanoma vaccine, raising questions about potential information leakage and insider trading. This adds regulatory and market scrutiny but does not itself indicate an FDA decision. Article: What Is Moderna Answering As FDA Vaccine Betting Markets Grow?

Moderna Trading Up 3.4%

Shares of MRNA opened at $228.44 on Wednesday. Moderna, Inc. has a one year low of $22.28 and a one year high of $254.48. The stock has a 50-day moving average price of $185.79 and a 200 day moving average price of $88.36. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The company has a market capitalization of $91.20 billion, a P/E ratio of -28.59 and a beta of 1.16.

Insider Transactions at Moderna

In related news, President Stephen Hoge sold 39,145 shares of Moderna stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $220.72, for a total value of $8,640,084.40. Following the completion of the sale, the president owned 1,636,565 shares in the company, valued at approximately $361,222,626.80. The trade was a 2.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Jamey Mock sold 34,836 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the sale, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is currently owned by corporate insiders.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.